Therapy-Related Leukemia following Docetaxel Chemotherapy for Metastatic Hormone-Sensitive Prostate Cancer: A Case Report
Introduction: Docetaxel is the first-line drug that has been proved to improve the overall survival of men with metastatic hormone-sensitive prostate cancer (mHSPC). For patients who survive the prostate cancer, they may be at risk of secondary neoplasm, especially for the therapy-re...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2024-12-01
|
| Series: | Case Reports in Oncology |
| Online Access: | https://karger.com/article/doi/10.1159/000541722 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction:
Docetaxel is the first-line drug that has been proved to improve the overall survival of men with metastatic hormone-sensitive prostate cancer (mHSPC). For patients who survive the prostate cancer, they may be at risk of secondary neoplasm, especially for the therapy-related myelodysplastic syndrome or therapy-related acute myeloid leukemia (t-AML).
Case Presentation:
We reported a 44-year-old man with prostate cancer (cT4N1M1c) who developed t-AML following docetaxel chemotherapy. Typically, the t-AML in our case was characterized by an aberrant karyotype t(15;17)(q22;q21).
Conclusions:
This case is, to our knowledge, the first time to report a patient with mHSPC who developed therapy-related acute promyelocytic leukemia following docetaxel chemotherapy, suggesting that docetaxel might contribute to the induction of t-AML.
|
|---|---|
| ISSN: | 1662-6575 |